Nephropathy following type 2 diabetes mellitus in Tunisian population

West Indian Medical Journal

Volumn 61, Issue 9, 2012, Pages 881-889

  Bouaziz, A ^a   Zidi, I ^b   Zidi, N ^c   Mnif, W ^a,d   Zinelabidine, H T ^e  

^a Laboratory of Basic Health Group   (Tunisia)

^b FACULTÉ DES SCIENCES DE TUNIS   (Tunisia)

^c IBN EL JAZZAR Medicine Faculty   (Tunisia)

^d Biotechpole Sidi Thabet   (Tunisia)

^e Basic Health Group   (Tunisia)

Author keywords

Glomerular filtration rate (GFR); Nephropathy; Retinopathy; Type 2 diabetes mellitus

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; CREATININE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; UREA;

ADULT; AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CONTROLLED STUDY; CREATININE CLEARANCE; CREATININE URINE LEVEL; CROSS-SECTIONAL STUDY; DIABETIC NEPHROPATHY; DISEASE DURATION; DISEASE PREDISPOSITION; DYSLIPIDEMIA; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; KIDNEY DYSFUNCTION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHENOTYPE; PREVALENCE; RETINOPATHY; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; TUNISIAN; UREA BLOOD LEVEL; AGED; BLOOD; DEVELOPING COUNTRY; DIABETIC RETINOPATHY; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; TUNISIA;

AGE FACTORS; AGED; BODY MASS INDEX; CREATININE; CROSS-SECTIONAL STUDIES; DEVELOPING COUNTRIES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIABETIC RETINOPATHY; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; TUNISIA;

EID: 84886741032     PISSN: 00433144     EISSN: None     Source Type: Journal    
DOI: 10.7727/wimj.2012.053     Document Type: Article

References (47)

1. Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 2005; 28: 164-76
2. Pagenkemper JJ. Diabetes Mellitus. In: Byham-Gray LD, Burrowes, JD, Chertow, GM, eds. Nutrition in Kidney Disease. Totowa, NJ: Humana Press Inc; 2008: 137-76
3. Ambady R, Chamukuttan S. Early diagnosis and prevention of diabetes in developing countries. Rev Endocr Metab Disord 2008; 9: 193-201
4. Locatelli F, Canaud B, Eckardt KU, Stenvinkel P,Wanner C, Zoccali C. The importance of diabetic nephropathy in current nephrological practice. Nephrol Dial Transplant 2003; 18: 1716-25
5. Ritz E. Limitations and future treatment options in Type 2 diabetes with renal impairment. Diabetes Care 2011; 34: S330-S4
6. Bakris GL. Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with Type 2 diabetes mellitus. Mayo Clin Proc 2011; 86: 444-56
7. Jermendy G, Ruggenenti P. Preventing microalbuminuria in patients with Type 2 diabetes. Diabetes Metab Res Rev 2007; 23: 100-10
8. Jerums G, Panagiotopoulos S, Premaratne E, MacIsaac RJ. Integrating albuminuria and GFR in the assessment of diabetic nephropathy. Nat Rev Nephrol 2009 5: 397-406
9. Tietz NW. Clinical guide to laboratory tests. 3rd ed. Philadelphia, USA: WB Saunders; 1995: 268
10. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2005; 28: S37-S42
11. American Diabetes Association. Hypertension management in adults with diabetes. Diabetes Care 2004; 27: S65-S7
12. Feldt-Rasmussen B. Microalbuminuria and clinical nephropathy in Type 1 (insulin-dependent) diabetes mellitus: pathophysiological mechanisms and intervention studies. Dan Med Bull 1989; 36: 405-15
13. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-70
14. Fontseré N, Salinas I, Bonal J, Bayés B, Riba J, Torres F et al. Are prediction equations for glomerular filtration rate useful for the longterm monitoring of Type 2 diabetic patients? Nephrol Dial Transplant 2006; 21: 2152-8
15. Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW et al. Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 2007; 53: 766-72
16. National Kidney Foundation. Calculator for Healthcare Professionals. Available from: http://kidney.org/professionals/kdoqi/gfr_calculator. cfm
17. Ohta M, Babazono T, Uchigata Y, Iwamoto Y. Comparison of the prevalence of chronic kidney disease in Japanese patients with Type 1 and Type 2 diabetes. Diabet Med 2010 27: 1017-23
18. Hasslacher C. Natural course of diabetic nephropathy. In: Hasslacher C, ed. Diabetic nephropathy. Chichester, UK: JohnWiley & Sons; 2001: 18-37
19. Bouzid C, Smida H, Kacem A, Turki Z, Ben Salem L, Ben Rayana C et al. Renal failure in Tunisian patients with Type 2 diabetes: frequency and related factors. Tunis Med 2011; 89: 10-5
20. Harzallah F, Alberti H, Kanoun F, Elhouch F, Slimane H. Quality of care of patients with Type 2 diabetes in a Tunisian university hospital. Diabetes Metab 2004; 30: 523-6
21. nd ed. Totowa, NJ: Humana Press Inc; 2005: 367-80
22. Sarafidis PA, Bakris GL. Microalbuminuria and chronic kidney disease as cardiovascular risk factors. In: Fonseca VA, editor. Cardiovascular endocrinology: shared pathways and clinical crossroads. New York, NY: Humana Press Inc; 2009: 149-67
23. Kravaritou M, Thanopoulou A, Karamanos B, Kofinis A, Noutsou M, Spanou E et al. Evidence that even 'normal' albuminuria may denote incipient GFR reduction in patients with Type 2 diabetes mellitus. Diabetes Res Clin Pract 2009; 85: 317-21
24. Mahjoub F, Gamoudi A, Jamoussi H, Gaigi S, Blouza-Chabchoub S. Metabolic profile of Tunisian obese adult. Tunis Med 2010; 88: 394-8
25. National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007; 49: S12-S154
26. Kramer H, Molitch ME. Screening for kidney disease in adults with diabetes. Diabetes Care 2005; 28: 1813-6
27. Snyder RW, Berns JS. Use of insulin and oral hypoglycaemic medications in patients with diabetes mellitus and advanced kidney disease. Semin Dial 2004; 17: 365-70
28. Reilly JB, Berns JS. Selection and dosing of medications for management of diabetes in patients with advanced kidney disease. Semin Dial 2010; 23: 163-8
29. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000; 36: 646-61
30. Tobe S. Update on calcium antagonists and the kidney. Curr Opin Nephrol Hypertens 2003; 12: 309-15
31. Ravera M, Ratto E, Vettoretti S, Parodi D, Deferrari G. Prevention and treatment of diabetic nephropathy: the program for irbesartan mortality and morbidity evaluation. J Am Soc Nephrol 2005; 16: S48-S52
32. Mercado C, Jaimes EA. Cigarette smoking as a risk factor for atherosclerosis and renal disease: novel pathogenic insights. Curr Hypertens Rep 2007; 9: 66-72
33. Hua P, Feng W, Ji S, Raij L, Jaimes EA. Nicotine worsens the severity of nephropathy in diabetic mice: implications for the progression of kidney disease in smokers. Am J Physiol Renal Physiol 2010; 299: F732-F739
34. Hansen HP, Tauber-Lassen E, Jensen BR, Parving HH. Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy. Kidney Int 2002; 62: 220-8
35. Robertson L, Waugh N, Robertson A. Protein restriction for diabetic renal disease. Cochrane Database Syst Rev 2007; 4: CD002181
36. Koya D, Haneda M, Inomata S, Suzuki Y, Suzuki D, Makino H et al. Long-term effect of modification of dietary protein intake on the progression of diabetic nephropathy: a randomised controlled trial. Diabetologia 2009; 52: 2037-45
37. Nakamura H, Mizuno K, Ohashi Y, Yoshida T, Hirao K, Uchida Y et al. Pravastatin and cardiovascular risk in moderate chronic kidney disease. Atherosclerosis 2009; 206: 512-7
38. Remuzzi G, Macia M, Ruggenenti P. Prevention and treatment of diabetic renal disease in Type 2 diabetes: the BENEDICT study. J Am Soc Nephrol 2006; 17: S90-S7
39. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 1456-62
40. BarnettA. Preventing renal complications in Type 2 diabetes: results of the diabetics exposed to telmisartan and enalapril trial. J Am Soc Nephrol 2006; 17: S132-S5
41. Düsing R, Sellers F. ACE inhibitors, angiotensin receptor blockers and direct renin inhibitors in combination: a review of their role after the ONTARGET trial. Curr Med Res Opin 2009; 25: 2287-301
42. Mtiraoui N, Ezzidi I, Turki A, Chaieb M, Mahjoub T, Almawi WY. Renin-angiotensin-aldosterone system genotypes and haplotypes affect the susceptibility to nephropathy in Type 2 diabetes patients. J Renin AngiotensinAldosterone Syst 2011; DOI: 10.1177/1470320310396542
43. Chavers BM, Mauer SM, Ramsay RC, Steffes MW. Relationship between retinal and glomerular lesions in IDDM patients. Diabetes 1994; 43: 441-6
44. Delcourt C, Villatte-Cathelineau B, Vauzelle-Kervroedan F, Papoz L. Clinical correlates of advanced retinopathy in Type 2 diabetic patients: implications for screening. The CODIAB-INSERM-Zeneca Pharma Study Group. J Clin Epidemiol 1996; 49: 679-85
45. Bergner R, Lenz T, Henrich DM, Hoffmann M, Uppenkamp M. Proteinuria in diabetic patients-is it always diabetic nephropathy? Kidney Blood Press Res 2006; 29: 48-53
46. Lee GS. Retarding the progression of diabetic nephropathy in Type 2 diabetes mellitus: focus on hypertension and proteinuria. Ann Acad Med Singapore 2005; 34: 24-30
47. Tu ST, Chang SJ, Chen JF, Tien KJ, Hsiao JY, Chen HC et al. Prevention of diabetic nephropathy by tight target control in an asian population with Type 2 diabetes mellitus: a 4-year prospective analysis. Arch Intern Med 2010; 170: 155-61